On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.

On the heels of a $42 million supply contract with the U.S. Department of Defense, France’s Valneva has netted another big funding source. Through a loan with…

After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National…

Lending its vaccines expertise to a leading Zika candidate, Sanofi has teamed up with the U.S. Army’s Walter Reed Army Institute of Research to guide an…

Building on previous vaccine collaborations in anthrax and pandemic flu, Gaithersburg, MD-based Emergent BioSolutions is moving its BARDA dealings into the…

Last July, WHO recommended that GlaxoSmithKline’s malaria vaccine Mosquirix be examined in pilot programs before introduction through large immunization…

As HIV researchers around the globe work to advance vaccines against the devastating virus, the NIAID has awarded $17.3 million to the University of…

The worldwide Zika vaccine race has reached a new milestone as Plymouth Meeting, PA’s Inovio Pharmaceuticals says it has received the first approval to begin…